ABLIVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1648 SEK | +1.10% |
|
+3.26% | -32.87% |
| Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
Business Summary
Number of employees: 8
Sales per Business
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Mitochondrial Diseases
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Sales per region
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Director of Finance/CFO | 57 | 13-11-30 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-31 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 07-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
Roger Franklin
BRD | Director/Board Member | 45 | 20-05-19 |
Denise Goode
BRD | Director/Board Member | 66 | 18-04-26 |
| Director/Board Member | 64 | 17-04-26 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,056,299,165 | 930,212,762 ( 88.06 %) | 0 | 88.06 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.87% | 20.28M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABLI Stock
- Company Abliva AB
